4870 results about "Micelle" patented technology

The image stability of electrophoretic media, comprising a plurality of particles disposed in a fluid and capable of moving through the fluid upon application of an electric field to the medium, can be improved by including in the fluid either a polystyrene or an aggregating diblock copolymer which forms micelle-like structures in the fluid, the diblock copolymer having a first block soluble in the fluid and a second block not swellable by the fluid. In variable transmission electrophoretic media, haze can be reduced by using as the fluid a mixture of a partially hydrogenated aromatic hydrocarbon and a terpene.

The present invention relates to a method of producing particles having a particle size of less than 100 nm and surface areas of at least 20 m2 / g where the particles are free from agglomeration. The method involves synthesizing the particles within an emulsion having a 1-40% water content to form reverse micelles. In particular, the particles formed are metal oxide particles. The particles can be used to oxidize hydrocarbons, particularly methane.

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.

The invention provides a water soluble complex comprising an inner core of a metal or semi-conductor nanoparticle. The nanoparticle is coated with a hydrophobic ligand, which is encapsulated in a micelle. In an aqueous medium, the micelle comprises a hydrophilic shell and a hydrophobic core, the hydrophilic shell comprising a plurality of hydrophilic moieties, the hydrophobic core comprising a plurality of hydrophobic moieties, each hydrophobic moiety comprising at least one chain, each chain comprising a minimum of 8 atoms; wherein the total number of atoms in all chains for each moiety comprises at least 24 atoms. The micelle has a minimum average diameter of approximately 5 nm and a maximum average diameter of approximately 45 nm.

Systems and methods that control the size and composition of emulsified droplets, multi-lamellar and asymmetric vesicles, encapsulation of reagents, membrane proteins, and sorting of vesicles / droplets. More particularly, microfluidic devices for controlled viscous shearing of oil-water emulsions of micro- and nano-scale droplets, the subsequent formation of amphiphilic vesicles such as liposomes, polymer vesicles, micelles, and the like, the post-assembly and post-processing of the droplets including splitting, fusing, sorting and the like, polymer emulsions, and the integration of amphiphilic vesicle production-line on a single microfluidic chip. Preferably, the microfluidic device enables oil-water co-flows with tunable viscous shear forces higher than the immiscible interfacial tension forces that generate favorable conditions for droplet formation.

A curable flame retardant epoxy resin composition including (a) at least one flame retardant epoxy resin; (b) at least one amphiphilic block copolymer; and (c) a curing agent. Such components are present in the curable composition in the appropriate amounts and ratios such that, upon curing, the block copolymer self-assembles into a nano structure morphology, such as a worm-like micelle morphology. The resulting cured product made from the composition of the present invention has a remarkably increased high fracture resistance; and allows the use of flame retardant epoxies in applications where fracture resistance is an issue.

The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.

A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: water and micelles comprising paclitaxel and a pharmaceutically-acceptable, water-miscible solubilizer forming the micelles, the solubilizer selected from the group consisting of solubilizers having the general structuresR1COOR2, R1CONR2, and R1COR2,wherein R1 is a hydrophobic C3-C50 alkane, alkene or alkyne and R2 is a hydrophilic moiety. The solubilizer is selected such that it does not have a pKa less than about 6.

This invention discloses compositions of chloroquine-coupled active agents such as therapeutic antibodies or insulin, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the drug is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to a drug directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing the drug for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and antibody or insulin to their site of action.

A method for encapsulating nucleic acids, particularly siRNAs, shRNAs, microRNAs, gene therapy plasmids, and other oligonucleotides in biodegradable polymers is disclosed, whereby the nucleic acids are formulated into reverse micelles composed of non-toxic and / or naturally-occurring lipids prior to nanoparticle formation by nanoprecipitation. This method can be coupled to other techniques that improve intracellular drug targeting, ultimately enhancing intracellular delivery of the aforementioned nucleic acids.

Fluids viscosified with viscoelastic surfactants (VESs) may have their viscosities reduced (gels broken) by the direct or indirect action of a composition that contains at least one metal ion source and optionally at least one second source. An optional second source may be a chelating agent where at least one reducing agent source may be additionally optionally used. Another optional component with the metal ion source includes a second, different metal ion source. The breaking composition is believed to directly attack the VES itself, possibly by disaggregating or otherwise attacking the micellar structure of the VES-gelled fluid, and / or possibly by changing the chemical structure of the VES to give two or more products.

PCT No. PCT / SE97 / 00287 Sec. 371 Date Sep. 17, 1998 Sec. 102(e) Date Sep. 17, 1998 PCT Filed Feb. 20, 1997 PCT Pub. No. WO97 / 30726 PCT Pub. Date Aug. 28, 1997Lipid-containing particles such as iscoms, iscom-matrix or vesicles such as micelles or liposomes that comprise one or more hydrophobic receptor molecules for targeting and antigenic substances, which receptor molecules have been integrated in the particle and are chosen from lipid-containing receptors or receptors that are hydrophobic, which receptor molecules bind to the antigenic substances.

Hydrophobic drugs become more practical for treatments by being encapsulated in micelle compositions for increasing solubility. Micelle compositions may include an excipient tocopherol and / or prodrug formulations of the drug. Micelles extend the time period the drug remains in the micelles to improve drug circulation time and thereby drug delivery. Hydrophobic drugs for micelle encapsulation may include rapamycin, geldanamycin, and paclitaxel. Administration of these micelle compositions does not require Cremophor EL or Tween 80, avoiding serious side effects associated with these products which would previously accompany such drug administration.

The invention relates to a middle fraction oil type hydrocracking catalyst, which consists of amorphous silicon aluminum, alumina, adhesive, high-silicon Y and beta composite molecular sieve, VIB group metal oxide, VIII group metal oxide and IA group metal element. The catalyst is characterized in that a high-silicon beta molecular sieve efficiently synthesized by a plate micelle method and a modified Y molecular sieve are used as main acid components of the catalyst, and the IA group metal element is used for carrier modification, wherein the synthesis of the beta molecular sieve is characterized in that the beta molecular sieve is synthesized directly by one step and does not need post modification treatment; and the beta molecular sieve and the modified Y molecular sieve are compounded to play a good role in synergy and complementation and used for the heavy-oil hydrocracking catalyst. The catalyst shows high hydrocracking activity and middle fraction oil selectivity.

It has been discovered that fluids viscosified with viscoelastic surfactants (VESs) may have their viscosities reduced (gels broken) by the direct or indirect action of a biochemical agent, such as bacteria, fungi, and / or enzymes. The biochemical agent may directly attack the VES itself, or some other component in the fluid that produces a by-product that then causes viscosity reduction. The biochemical agent may disaggregate or otherwise attack the micellar structure of the VES-gelled fluid. The biochemical agent may produce an enzyme that reduces viscosity by one of these mechanisms. A single biochemical agent may operate simultaneously by two different mechanisms, such as by degrading the VES directly, as well as another component, such as a glycol, the latter mechanism in turn producing a by-product (e.g. an alcohol) that causes viscosity reduction. Alternatively, two or more different biochemical agents may be used simultaneously. In a specific, non-limiting instance, a brine fluid gelled with an amine oxide surfactant can have its viscosity broken with bacteria such as Enterobacter cloacae, Pseudomonas fluorescens, Pseudomonas aeruginosa, and the like.

Amphiphilic peptide compounds comprising one or more epitope sequences for binding interaction with one or more corresponding growth factors, micellar assemblies of such compounds and related methods of use.

The present invention provides a method for the synthesis of unagglomerated, highly dispersed, stable core / shell nanocomposite particles comprised of preparing a reverse micelle microemulsion that contains nanocomposite particles, treating the microemulsion with a silane coupling agent, breaking the microemulsion to form a suspension of the nanocomposite particles by adding an acid / alcohol solution to the microemulsion that maintains the suspension of nanocomposite particles at a pH of between about 6 and 7, and simultaneously washing and dispersing the suspension of nanocomposite particles, preferably with a size exclusion HPLC system modified to ensure unagglomeration of the nanocomposite particles. The primary particle size of the nanocomposite particles can range in diameter from between about 1 to 100 nm, preferably from between about 10 to 50 nm, more preferably about 10 to 20 nm, and most preferably about 20 nm.

A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: water and micelles comprising paclitaxel and a pharrnaceutically-acceptable, water-miscible solubilizer forming the micelles, the solubilizer selected from the group consisting of solubilizers having the general structureswherein R1 is a hydrophobic C3-C50 alkane, alkene or alkyne and R2 is a hydrophilic moiety. The solubilizer is selected such that it does not have a pKa less than about 6.

A mixed micellar aerosol pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, at least three micelle forming compounds, a phenol and a propellant. The micelle forming compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof. The amount of each micelle forming compound is present in a concentration of from 1 to 20 wt. / wt. % of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt. / wt. % of the formulation. The propellant, e.g. a fluorocarbon propellant, provides enhanced absorption of the pharmaceutical agent.

Temperature- and pH-responsive copolymer compositions, and drug delivery devices, conjugates, nanoparticles, and micelles that include the compositions.

The present invention relates to whey protein micelles, particularly to whey protein micelle concentrates or powders thereof and to a method for producing them. The present invention also pertains to the use of these micelles concentrates or powders thereof in nutrition and / or cosmetics and / or pharmaceutics.

The image stability of electrophoretic media, comprising a plurality of particles disposed in a fluid and capable of moving through the fluid upon application of an electric field to the medium, can be improved by including in the fluid either a polystyrene or an aggregating diblock copolymer which forms micelle-like structures in the fluid, the diblock copolymer having a first block soluble in the fluid and a second block not swellable by the fluid. In variable transmission electrophoretic media, haze can be reduced by using as the fluid a mixture of a partially hydrogenated aromatic hydrocarbon and a terpene.

The invention discloses an alumina carrier and a preparation method thereof. In the alumina carrier, aluminum hydroxide gel prepared by a molten salt supersolubilizing micelle method is taken as a raw material. After a surfactant and a hydrocarbon component contained in the gel are molded and baked, nano-alumina particles formed by removing water from the polymerized aluminum hydroxide still have a basic rod-shaped structure and are piled up in an unordered way so as to form a frame structure. The alumina carrier has the characteristics of large pore volume, large pore diameter, high porosity, large orifice on the outer surface and high pore canal penetrability. In particular for macromolecules, the alumina carrier prevents catalyst inactivation caused by the blocking of an ink bottle-shaped orifice, so that impurity deposition is increased, and the running period of a catalyst is prolonged. The alumina carrier can be applied to a catalytic reaction which contains a macromolecule reactant or a macromolecule product.